given mix exposur deferr emerg procedur plu
ventil monitor equip name investor
put middl categori impact
spent time go exposur busi busi
came away feel increment better good better compani
overal sale exposur come month
given commit employe expect substanti
de-lever continu like environ
particularli given offset like respiratori monitor busi
sale strong capit posit cash debt highli innov
pipelin share trade new calendar ep forecast
new forecast view attract environ
well-fund rel well-posit compani weather
storm potenti subsequ econom downturn
start posit compani ramp product
ventil effort allevi current world-wide shortag
sale airway ventil typic annual
overal sale expect increas significantli medtron
produc ventil per week date
plan hit per week end june product shift
almost exclus pb high-end ventil cost
design specif sever ill patient high-acu
set addit made publicli avail design
code pb ventil effort address shortag
product rest respiratori gastrointestin renal
franchis sale also high demand patient
monitor busi focus sale oxygen anesthesia
perfus monitor informat driven predominantli sale
compani nellcor puls oximetri platform crucial care
patient current high demand poc
icu small portion franchis renal busi also well-
insul given emerg natur renal failur on-going care
look balanc mitg busi surgic innov
sale mix bag product split
use deferr emerg procedur one
hand sale bariatr surgeri joint replac exampl
highli deferr impact oncolog procedur
could put well given high-risk expos cancer patient
though delay long hand
appendectomi trauma bowel obstruct emerg happen
sourc style exposur morgan quantit deriv strategi tabl compani data morgan estim
page analyst certif import disclosur
 morgan seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report singl
factor make invest decis
summari invest thesi valuat
past year weve seen signific turnaround
perform manag return
consist exceed expect importantli
materi improv gener
stick point mani investor next month
believ medtron grow least plu see
number underappreci data present
transform new product launch appear
fulli appreci street conserv leav
potenti catalyst see come upsid vs
forecast manag set appropri
conserv bar long-rang top-lin earn
progress june analyst day see meaning
upsid street estim year ahead potenti
multipl expans sustain execut
dec price target share
base calendar price-to-earnings multipl slight discount
large-cap med-tech peer set appli calendar
million
cash-flow oper
margin growth
 morgan quantit deriv strategi perform driver compani data bloomberg morgan estim tabl
turn diabet
busi
overal sale
also
predominantli well-insul headwind given non-
procedur semi-recur revenu natur life-long natur condit
recur revenu busi model make busi better-posit
environ believ seen notabl amount
stock consum certain extent well though
could off-set slow new patient start patient renew
typic requir in-person offic visit hands-on train virtual visit
on-line train endocrinologist possibl expect mani
patient like hold pandem subsid without approv yet
pump continu expect neg sale like
exacerb
cvg impact heart failur sale mix
lvad repres one procedur impact
atrial fibril procedur postpon long due
risk stroke mani patient physician will temporarili postpon
send patient home monitor ensur condit
deterior sale implant diagnost significantli slow doctor
like prescrib holter monitor irhythm zio zio
administ remot bring patient later linq
implant turn pacemak procedur temporarili
defer procedur patient critic condit
pacemak depend need replac still perform risk
lower icd procedur even replac
put period time
case similar aortic peripher coronari structur heart
start coronari structur heart sale major
stent case emerg still perform asid patient
stabl angina case begun see tavr
procedur postpon outbreak worsen sever
case perform aortic peripher sale also mix
deferrable/emerg exposur depend case sever gener
deferr though endoven procedur gener put rule
thumb away heart deferr
close rtg repres expos busi
like see impact spine sale pain
therapi sale like materi impact given highli
deferr natur procedur saw recent
week disrupt result reduct sale us
brain therapi sale ischem stroke procedur still
perform treat intact brain aneurysm physician take
watch wait approach previous unthink sale
like come signific pressur due price tag hospit
budget significantli impact though placement may
made payment plan case similar specialti therapi
sale emerg brain procedur may perform though
major ent pelvic health procedur treat pain discomfort
put
mind expect experi materi neg
impact sale sale compani
oper calendar schedul experi week disrupt
number february-april much
materi impact compani expect see full quarter impact china
us europ materi impact late march like april top
slowdown deferr procedur volum hospit held back
typic end-of-quart bulk order seek cut cost draw
current inventori without fulli replenish suppli impact
compani med-tech especi quarter year
cut could off-set though abil drive signific
leverag limit commit pay employe first
like commend support sale rep factori employe
challeng time keep employ pay fairli
keep salesforc place also key support compani futur robust
pipelin cancel travel confer like sage
partial off-set vast major expens typic come employe
salari expect large-cap med-tech
compani abl cut sg given quarter without
turn rest enrol medtron
clinic trial put hold though on-going trial regulatori qualiti
effort still need support much abil ramp
product plu decis maintain factori worker gross margin
like impact forecast y/i
y/i lastli dollar strengthen local currenc
recent week particularli emerg market mean fx
increment neg impact vs prior forecast
begun see improv china dynam play
suggest rapid recoveri devic like post-covid
healthcar system china alreadi oper maximum
capac mean could take sever month even quarter
volum return previou level ad equat even
account healthcar expans countri experienc mean
isnt catch-up lost procedur sell-sid forecast incorpor
simpli wait time longer deferr procedur
perform precautionari measur put place like limit
rate recoveri includ ensur patient test
undergo procedur physician proper protect equip
import slow spread viru measur constrain
throughput hospit could place widespread vaccin avail
situat remain fluid could play wors europ
unit state given sever outbreak though medtron
begun see lost procedur volum last week deferr
non-deferr procedur impact hotspot like nyc
seattl financi capac healthcar system also play key role drive
time speed recoveri place like europ experienc sever
outbreak spend much budget battl may
suffici fund perform deferr procedur pandem subsid
lastli wouldnt surpris see tuck-in given today
attract valuat strong balanc sheet
suspens share repurchas med-tech gener
year though today environ may make find will buyer
challeng compani express interest revisit deal made
strateg sens though financi viabl time new ceo
step month dont expect sizabl riski
surpris see return small accret deal
lower dec price target
base calendar price-to-earnings multipl slight discount large-cap
med-tech peer set appli calendar ep estim
invest thesi valuat risk
past year weve seen signific turnaround perform
manag deliv four consecut beat-and-rais quarter
top- bottom-lin out-performance return consist exceed
expect importantli materi improv gener
stick point mani investor next month believ
grow least plu see number underappreci data
present transform new product launch appear fulli
appreci street conserv leav potenti catalyst
see come upsid vs forecast manag set appropri
conserv bar long-rang top-lin earn progress june
analyst day see meaning upsid street estim year ahead
potenti multipl expans sustain execut
dec price target share base calendar price-to-earnings
multipl slight discount large-cap med-tech peer set appli
calendar ep estim see appropri given compani in-
line outlook longer term off-set modest headwind near term
risk rate price
downsid risk includ slower growth and/or increas competit core end
market slower anticip adopt new technolog poor
deploy capit lack gener
medtron plc summari financi
cash equival
flow oper activ
o/w chang work capit
flow invest activ
sale
flow financ activ
net chang cash
adj free cash flow firm
compani report morgan estim
note million except per-shar data fiscal year end apr o/w
analyst certif research analyst denot ac cover report certifi multipl research
analyst primarili respons report research analyst denot ac cover within document
individu certifi respect secur issuer research analyst cover research view
express report accur reflect research analyst person view subject secur issuer
part research analyst compens directli indirectli relat specif recommend
view express research analyst report korea-bas research analyst list front cover applic
also certifi per kofia requir analysi made good faith view reflect opinion
without undu influenc intervent
author name within report research analyst unless otherwis specifi europ sector specialist may shown
report contact author report part research depart
